Our research provides theoretical supports for combined therapeutic strategies in the future and offers optimal selection of patients treated with immunotherapy, so as to improve the outcomes of ER+/PR−/HER2− breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.